CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
Year: 2014
Type: article
Abstract: MYC dysregulation confers a poor prognosis to diffuse large B-cell lymphoma (DLBCL), and effective therapeutic strategies are lacking in relapsed/refractory DLBCL, Burkitt lymphoma and intermediate forms. 1 , 2 As a master transcriptional regulator, MYC recruits transcription complexes containing RNA polymerase II (Pol II) to facilitate effective transcriptional elongation of MYC gene targets. 3 Pol II is fully activated by phosphorylation of a critical serine residue at position 2 within heptapeptide repeats in the carboxy-terminal domain (CTD), a function performed by the positive transcription elongation factor b (P-TEFb; comprising CDK9 and cyclin T1). 4 It has been shown that MYC binds and recruits P-TEFb to its targets as a means to activate Pol II. 3 , 5 , 6 More recently, CDK9-mediated transcriptional elongation was reported as essential for tumor maintenance in a genetically defined MYC-driven model of hepatocellular carcinoma. 7 Thus, CDK9 dependence may represent a druggable vulnerability in lymphomas with dysregulated MYC expression.
Source: Leukemia
DOI: 10.1038/leu.2015.10
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funders: Veski, Arrow Bone Marrow Transplant Foundation, Ministerio de Economía y Competitividad, Consejería de Educación, Junta de Castilla y León, Junta de Castilla y León, Medical Research Council, National Health and Medical Research Council, Cancer Council Victoria, Instituto de Salud Carlos III, European Regional Development Fund
OpenAlex ID: W1982494540
